CannaPharmaRx flags $30.9M working-capital deficit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
CannaPharmaRx, Inc. (CPMD) reported third-quarter revenue of $137,705, versus $656,606 a year earlier, and net income of $645,416, versus a $1,477,811 loss. Revenue reflected lower sales volumes and no Cantek sales in the quarter. Net income included $1,728,677 in noncash fair-value gains on derivative conversion features and $181,693 on the obligation to issue shares, alongside an operating loss of $532,943. For the first nine months, revenue was $1,041,385 and net loss was $1,645,647, compared with $1,223,533 and $3,581,863 a year earlier.
At September 30, 2026, cash was $32,037, working-capital deficiency was $30,929,128, and related-party loans payable were $14,382,683, all current. The company said existing cash was insufficient for current operations and substantial doubt existed about its ability to continue as a going concern; it depends on related-party funding. In October 2026, it sold 400,000 grams of cannabis to a related party for CAD 680,000. On November 5, 2026, the board approved extending forbearance through December 31, 2026, and extending maturities of Mr. Tal and Koze LTB-related notes to December 31, 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly reported income was $645,416, including noncash fair-value gains.
- Moderate pointNine-month net loss was $1,645,647, compared with $3,581,863 a year earlier.
Negative
- Major pointSubstantial doubt and a $30,929,128 working-capital deficiency at September 30, 2026.
- Moderate pointThird-quarter revenue was $137,705, versus $656,606 a year earlier.
Filing Explained
The approved share issuance remains incomplete, so its ownership dilution has not yet taken effect.
The 10-Q says the board approved issuance of 2,500,000 common shares to settle a dispute, but the shares had not been issued as of the report’s November 16, 2026 issuance date. If issued, these additional shares would increase the share count and reduce existing holders’ percentage ownership.
The board also waived return of 625,000 common shares from another shareholder.
An agreement effective October 31, 2026 terminated a side letter that gave Mr. Tal rights to appoint, remove, or replace three directors.
The report says the company’s ongoing supplier-funding arrangement with Koze has no stated limit, but Koze may discontinue it at any time, and the company depends on that funding for operations.
Key Figures
Key Terms
substantial doubt financial
working capital deficiency financial
derivative conversion feature financial
net realizable value financial
imputed interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were CPMD’s third-quarter 2026 revenue and earnings?
Why does CPMD report substantial doubt about continuing as a going concern?
What did CPMD’s November 2026 forbearance extension cover?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For the quarterly
period ended
or
For the transition period from ___________to ___________
Commission File Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (IRS Employer ID No.) |
(Address of principal executive offices)
(Issuer’s Telephone Number)
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| OTC Pink Sheets |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days:
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check all applicable)
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐
Yes
The number of shares of the registrant’s
common shares outstanding as of November 10, 2026, was
CANNAPHARMARX, INC.
September 30, 2026
TABLE OF CONTENTS
| Page | ||
| PART I. FINANCIAL INFORMATION | ||
| Item 1 | Condensed Interim Consolidated Financial Statements (unaudited) | 3 |
| Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation | 26 |
| Item 3 | Quantitative and Qualitative Disclosures About Market Risk | 40 |
| Item 4 | Controls and Procedures | 41 |
| PART II. OTHER INFORMATION | ||
| Item 1 | Legal Proceedings | 43 |
| Item 1A | Risk Factors | 44 |
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 44 |
| Item 3 | Defaults Upon Senior Securities | 44 |
| Item 4 | Mine Safety Disclosures | 44 |
| Item 5 | Other Information | 44 |
| Item 6 | Exhibits | 45 |
| Signatures | 46 |
| 2 |
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
|
CANNAPHARMARX, INC. CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (in United States dollars) |
September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | $ | ||||||
| Goods and services tax receivable | ||||||||
| Accounts receivable (includes related party amounts, Note 5) | ||||||||
| Prepaid expense | ||||||||
| Inventory | ||||||||
| Total current assets | ||||||||
| Non-current assets | ||||||||
| Equipment, net | ||||||||
| Right-of-use building, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities (includes related party amounts, Note 5) | $ | $ | ||||||
| Accrued interest (includes related party amounts, Note 5) | ||||||||
| Deferred revenue (includes related party amounts, Note 5) | ||||||||
| Notes payable | ||||||||
| Convertible notes | ||||||||
| Derivative conversion feature | ||||||||
| Loans payable to related parties, current portion (Note 5) | ||||||||
| Royalty payable to related parties (Note 5) | ||||||||
| Liability for right-of-use building, current portion | ||||||||
| Obligation to issue shares - related party (Note 5) | ||||||||
| Total current liabilities | ||||||||
| Non-current liabilities | ||||||||
| Loans payable to related parties (Note 5) | ||||||||
| Liability for right-of-use building | ||||||||
| Total liabilities | ||||||||
| SHAREHOLDERS’ DEFICIT | ||||||||
| Preferred shares series A, $ | ||||||||
| Preferred shares series B, $ | ||||||||
| Preferred shares series C, $ | ||||||||
| Common shares, $ | ||||||||
| Shares to be issued | ||||||||
| Treasury shares, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive income (loss) | ( | ) | ||||||
| Total shareholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and shareholders’ deficit | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.
| 3 |
|
CANNAPHARMARX, INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) For the three and nine months ended September 30, 2026 and 2025 (in United States dollars) (Unaudited) |
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue (includes related party amounts, Note 5) | $ | $ | $ | $ | ||||||||||||
| Cost of goods sold (includes related party amounts, Note 5) | ||||||||||||||||
| Gross loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Operating expenses | ||||||||||||||||
| General and administrative (includes related party amounts, Note 5) | ||||||||||||||||
| Professional fees (includes related party amounts, Note 5) | ||||||||||||||||
| Royalty expense to related parties (Note 5) | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expenses) | ||||||||||||||||
| Change in the fair value of derivative conversion feature | ||||||||||||||||
| Change in the fair value of obligation to issue shares | ||||||||||||||||
| Foreign exchange gain (loss) | ( | ) | ( | ) | ||||||||||||
| Interest expense (includes related party amounts, Note 5) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Imputed interest expense to related parties (Note 5) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other expense | ( | ) | ||||||||||||||
| Total other income (expenses) | ( | ) | ( | ) | ( | ) | ||||||||||
| Income (loss) before income tax | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Income tax expense | ||||||||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Foreign currency translation adjustment | ( | ) | ( | ) | ||||||||||||
| Net comprehensive income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Basic income (loss) per share of common shares | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Diluted income (loss) per share of common shares | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of shares outstanding – basic | ||||||||||||||||
| Weighted average number of shares outstanding – diluted | ||||||||||||||||
Certain items in this report have been reclassified to conform to the current presentation in the financial statements (see Note 1).
The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.
| 4 |
|
CANNAPHARMARX, INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS For the nine months ended September 30, 2026 and 2025 (in United States dollars) (Unaudited) |
| Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Operating activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments for non-cash items: | ||||||||
| Amortization and depreciation | ||||||||
| Amortization and depreciation included in cost of goods sold | ( | ) | ( | ) | ||||
| Change in the fair value of derivative conversion feature | ( | ) | ( | ) | ||||
| Change in the fair value of obligation to issue shares | ( | ) | ( | ) | ||||
| Unrealized foreign exchange loss | ( | ) | ||||||
| Interest expense | ||||||||
| Imputed interest expense | ||||||||
| Other expense | ||||||||
| Bad debt expense | ||||||||
| Loss on impairment of inventory included in cost of goods sold | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Goods and services tax receivable | ||||||||
| Prepaid expenses | ( | ) | ||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Inventory | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ||||||
| Royalty payable | ||||||||
| Accounts payable and accrued liabilities | ||||||||
| Cash used in operating activities | ( | ) | ( | ) | ||||
| Investing activities | ||||||||
| Purchases of equipment | ( | ) | ||||||
| Cash used in investing activities | ( | ) | ||||||
| Financing activities | ||||||||
| Proceeds from related party loans | ||||||||
| Cash provided by financing activities | ||||||||
| Effect of exchange rate changes on cash | ( | ) | ||||||
| Net change in cash | ( | ) | ||||||
| Cash, beginning of period | ||||||||
| Cash, end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for income taxes | $ | $ | ||||||
| Cash paid for interest expense | $ | $ | ||||||
| Supplemental disclosure of non-cash financing and investing activities: | ||||||||
| Cash received by related parties directly from customers | $ | $ | ||||||
| Cash paid by related parties directly to suppliers | $ | $ | ||||||
| Repayment of related party loans and interest by Koze on behalf of the Company | $ | |||||||
| Settlement of note payable and accrued interest through the issuance of shares | $ | $ | ||||||
| Reclassification of notes payable to loans payable to related parties | $ | $ | ||||||
| Reclassification of convertible notes to loans payable to related parties | $ | $ | ||||||
| Adjustment for related party loan modification included in additional paid-in capital | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.
| 5 |
|
CANNAPHARMARX, INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT (in United States dollars) (Unaudited) |
Preferred Series A | Preferred Series B | Preferred Series C | Common Shares | Shares to be issued | Treasury Shares | |||||||||||||||||||||||||||||||||||||||||||
| Number | Number | Number | Number | Number | Number | |||||||||||||||||||||||||||||||||||||||||||
| of shares | Value | of shares | Value | of shares | Value | of shares | Value | of shares | Value | of shares | Value | |||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2025 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
| Related party loan modification, adjustment | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
| Shares to be issued | – | – | – | – | – | |||||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2025 | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of common shares | – | – | – | ( | ) | ( | ) | – | ||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2026 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
| Shares issued on settlement of debt | – | – | – | – | – | |||||||||||||||||||||||||||||||||||||||||||
| Related party loan modification, adjustment | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net loss | – | – | – | – | – | – | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2026 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
| Change in foreign currency translation | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Net income | – | – | – | – | – | – | ||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | $ | $ | $ | $ | $ | – | $ | |||||||||||||||||||||||||||||||||||||||||
(continued)
The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.
| 6 |
| Additional | Accumulated Other | Total | ||||||||||||||
| Paid-in | Accumulated | Comprehensive | Shareholders’ | |||||||||||||
| Capital | Deficit | (Loss) Income | Deficit | |||||||||||||
| Balance, December 31, 2024 | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Change in foreign currency translation | – | – | ( | ) | ( | ) | ||||||||||
| Net loss | – | ( | ) | – | ( | ) | ||||||||||
| Balance, March 31, 2025 | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Change in foreign currency translation | – | – | ( | ) | ( | ) | ||||||||||
| Net loss | – | ( | ) | – | ( | ) | ||||||||||
| Balance, June 30, 2025 | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Related party loan modification, adjustment | – | – | ||||||||||||||
| Change in foreign currency translation | – | – | ||||||||||||||
| Net loss | – | ( | ) | – | ( | ) | ||||||||||
| Balance, September 30, 2025 | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Shares to be issued | – | – | ||||||||||||||
| Change in foreign currency translation | – | – | ( | ) | ( | ) | ||||||||||
| Net loss | – | ( | ) | – | ( | ) | ||||||||||
| Balance, December 31, 2025 | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Issuance of common shares | ||||||||||||||||
| Change in foreign currency translation | – | – | ||||||||||||||
| Net loss | – | ( | ) | – | ( | ) | ||||||||||
| Balance, March 31, 2026 | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Shares issued on settlement of debt | – | – | ||||||||||||||
| Related party loan modification, adjustment | – | – | ||||||||||||||
| Change in foreign currency translation | – | – | ||||||||||||||
| Net loss | – | ( | ) | – | ( | ) | ||||||||||
| Balance, June 30, 2026 | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
| Change in foreign currency translation | – | – | ( | ) | ( | ) | ||||||||||
| Net income | – | – | ||||||||||||||
| Balance, September 30, 2026 | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||
The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.
| 7 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
CannaPharmaRx, Inc. was originally incorporated in the state of Colorado in August 1998 as Network Acquisitions, Inc and was subsequently reincorporated in Delaware. The Company underwent several name changes over the years and, in October 2014, changed its legal name to CannaPharmaRx, Inc. (hereinafter the “Company”). The Company focuses its business efforts on the acquisition, development and operation of cannabis cultivation facilities in Canada.
On January 1, 2022, the Company entered into a lease with Formosa Mountain Ltd. (“Formosa”) for the use of a facility located in Cremona, Alberta, Canada. The lease was amended and restated effective January 1, 2025 for a term of seventeen years expiring December 31, 2041, with two five-year extension options and basic rent of CAD 125,000 per month on a triple-net basis. The Company has concluded that the arrangement is an operating lease. During 2022, the Company recommissioned the 55,000 square foot facility (the “Facility”) into an indoor cannabis farm with 10 growing rooms and one drying and packing room. During 2025, the Company added one additional growing room to its operations. The Facility now has six growing rooms and one drying and packing room in operation and the Company plans to increase capacity over the next one to two years to open a second drying and packing room and to operate all 10 growing rooms.
The Company received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency on December 22, 2022, and commenced cannabis production during the year ended December 31, 2023. Our common shares are traded on the OTC Pink Sheets under the trading symbol “CPMD.”
Potential liability exposure and insurance coverage
The Company has not paid any insurance premiums since early 2024. As a result, its current insurance coverage has lapsed. The Company may be subject to claims for damages and other expenses that are not covered by insurance. The Company’s business, profitability, and growth prospects could be adversely affected in the event it is required to pay damages and incur defense costs in connection with a liability claim. There can be no assurance that the Company will be able to reinstate or obtain insurance coverage in the future in amounts, or at a cost, that would provide adequate protection.
Basis of presentation
The accompanying unaudited condensed interim consolidated financial statements (the “financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.
All figures are in United States (“US”) dollars (“USD”) unless indicated otherwise. All references to “CAD” are to Canadian dollars.
| 8 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)
Change in Classification
During the three months ended September 30, 2026, the Company refined its accounting for costs of goods sold and reclassified the idle-capacity portion of facility occupancy costs to general and administrative expenses when it was previously recorded as cost of goods sold. This reclassification was applied to comparative figures to conform to the current period’s presentation. For the three and nine months ended September 30, 2026, $65,246 and $197,785, respectively (2025 - $66,293 and $195,899, respectively), have been reclassified to general and administrative expenses from cost of goods sold. The reclassification had no effect on loss from operations, net income (loss), or shareholders’ deficit.
Foreign currency translation
As at September 30, 2026, the official closing
exchange rate for the translation of CAD to USD was
Earnings (loss) per share
Earnings (loss) per share is presented in accordance with Accounting Standards Codification, Earnings per Share (Topic 260), which requires the presentation of both basic and diluted earnings per share (“EPS”) on the income statements.
Basic EPS excludes any dilutive effects of share options, share purchase warrants, and convertible securities, but includes restricted common shares issued. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period.
Diluted EPS reflects the potential dilution that
would occur if securities or other contracts to issue common shares were exercised using the treasury stock method or converted to common
shares using the if-converted method. Diluted EPS calculations are determined by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents outstanding. Diluted EPS excludes all potential dilutive common shares
if their effect is anti-dilutive. As at September 30, 2026, convertible preferred shares outstanding totaled
Fair values of assets and liabilities
The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded, and the reliability of the assumptions used to determine fair value.
Level 1: Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
Level 2: Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.
Level 3: Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.
| 9 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The Company’s financial assets and liabilities comprise cash, accounts receivable, accounts payable and accrued liabilities, accrued interest, notes payable, convertible notes, derivative conversion feature, loans payable to related parties, royalty payable and obligation to issue shares.
The Company measures the fair value of its convertible notes’ derivative conversion feature and obligation to issue shares using Level 3 inputs.
There are no other financial assets or liabilities measured at fair value on a recurring basis presented on the Company’s balance sheet.
As at September 30, 2026, the carrying values of the Company’s financial instruments approximate their fair values.
Use of estimates
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates relate to the impairment of long-lived assets, the valuation of financial instruments, the valuation of inventory, the provision of income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as at the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.
In preparing these financial statements, the Company is exposed to the same sources of estimation uncertainty as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.
Significant Accounting Policies
There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2025.
| 10 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)
Recently issued accounting pronouncements
New accounting standards not yet adopted
In November 2024, the FASB issued ASU No. 2024-03, Income Statement Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires an entity to disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. It also requires an entity to include certain amounts that are already required to be disclosed under current GAAP in the same disclosure. Additionally, it requires an entity to disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and to disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. The amendments in the ASU are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. Management is currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.
NOTE 2 - GOING CONCERN AND LIQUIDITY
As at September 30, 2026, the Company had
cash of $
These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.
Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern. Management intends to address these liquidity challenges through debt financings and/or raise additional funding through equity financing to support ongoing operating expenses and working capital needs. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company and therefore, the Company is heavily reliant on funding from related parties. If the Company is unable to secure adequate financing or otherwise successfully implement its plans, it may be required to significantly reduce or curtail its operations, or cease operations entirely. Any issuance of equity securities to raise capital could result in substantial dilution to existing shareholders. Certain borrowings are secured by the Company’s assets, including equipment and receivables. In the event of default, lenders may have the right to seize collateralized assets. These consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
| 11 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 2 - GOING CONCERN AND LIQUIDITY (continued)
On March 17, 2025, the Company and its subsidiary, 2323414 Alberta Ltd. (“Alberta Ltd.”), which operates the Company’s principal business activities, including the cultivation, processing, and distribution of cannabis, entered into a security and royalty agreement with Koze Investments LLC (“Koze”), a California-based limited liability company engaged in providing financing and investment services. Koze has been a related party of the Company since March 11, 2025, the date on which its manager, Elliot Zemel, was appointed as a director of the Company. Pursuant to the agreement, Alberta Ltd. is required to pay a royalty on cannabis product sales from the prior month. If royalty payments are not made on time, the applicable rate increases. The agreement stipulates that a default occurs if Alberta Ltd. fails to make royalty or lease payments for three consecutive months, or for any four months within a rolling six-month period. As collateral, the Company granted Koze a security interest in its entire ownership interest in Alberta Ltd., which will remain in place until all obligations are fully satisfied. As at September 30, 2026, Alberta Ltd. was in default of its payment obligations. Koze had agreed to forbear from exercising its rights over the ownership interest until August 31, 2026, and the forbearance period expired on that date. See Note 9 for events subsequent to period end relating to the forbearance period.
NOTE 3 - INVENTORY
A summary of the Company’s inventory is as follows:
| Schedule of inventory | ||||||||
September 30, 2026 | December 31, 2025 | |||||||
| Finished goods | $ | $ | ||||||
| Work in process | ||||||||
| Inventory | $ | $ | ||||||
During the three and nine months ended September
30, 2026, the Company recognized inventory write-downs to net realizable value of $
The Company evaluates its inventory, including work in progress, at each reporting period to ensure it is stated at the lower of cost or net realizable value (“NRV”). NRV is defined as the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation.
If the estimated NRV of inventory is less than its recorded cost, the Company records a write-down to reflect the inventory at NRV. Such write-downs are recognized in cost of goods sold in the period identified.
| 12 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 4 – DERIVATIVE CONVERSION FEATURE
A summary of the Company’s derivative conversion feature arising from convertible notes for the nine months ended September 30, 2026 and the year ended December 31, 2025 is as follows:
| Schedule of derivative liabilities | ||||
| Balance, December 31, 2024 | $ | |||
| Changes in fair value of derivative conversion feature | ||||
| Balance, December 31, 2025 | ||||
| Changes in fair value of derivative conversion feature | ( | ) | ||
| Balance, September 30, 2026 | $ |
The Company used an option pricing model to calculate the derivative conversion feature. A summary of the Company’s weighted average inputs used in the model for the nine months ended September 30, 2026 and the year ended December 31, 2025 is as follows:
| Schedule of weighted average inputs for derivative liabilities valuation | ||||||||
| Period ended September 30, 2026 | Year ended December 31, 2025 | |||||||
| Share price | $ | $ | ||||||
| Exercise price | $ | $ | ||||||
| Risk-free interest rate | ||||||||
| Expected volatility | ||||||||
| Expected life | ||||||||
| Expected dividend yield | ||||||||
The risk-free interest rate was based on rates established by the Federal Reserve Bank. Beginning with the year ended December 31, 2025, the Company estimated expected volatility using a peer-based approach rather than the historical volatility of its own common shares. The Company’s common shares trade infrequently on the OTC Markets, and management determined that historical volatility derived solely from Company-specific trading data was not reflective of market-participant assumptions. As at the date of these financial statements, all convertible notes were past their maturity date and accordingly, the expected term of the conversion feature of the notes was assumed to be 1 year from the date of these financial statements. The expected annual dividend yield was based on the fact that the Company has not customarily paid dividends in the past and does not expect to pay dividends in the future.
NOTE 5 - RELATED PARTY TRANSACTIONS
A related party is any individual or entity that can exercise significant influence over the Company, or over which the Company can exercise significant influence. Related parties include affiliates, principal owners, directors, executive management, their immediate family members, and entities under common control. The Company has a significant amount of related party balances and transactions.
| a) | Key related party transactions |
A summary of the Company’s related party transactions is as follows:
| Schedule of related party transactions | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Lease expense due to Formosa included in cost of goods sold | ||||||||||||||||
| Lease expense due to Formosa included in general and administrative expense | ||||||||||||||||
| Professional fees | ||||||||||||||||
| Royalty expense | ||||||||||||||||
| Interest expense | ||||||||||||||||
| Imputed interest expense | ||||||||||||||||
| Other expense | ||||||||||||||||
| Marketing expense included in general and administrative expense | ||||||||||||||||
| Rent | ||||||||||||||||
| 13 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
Revenue
During the three and nine months ended
September 30, 2026, the Company recognized revenue of $nil
and $
Revenue from Cantek represents
Lease expense
The Company has a lease with Formosa, which became a related party upon the appointment of its manager, Elliot Zemel, as a director of the Company on March 11, 2025.
| Schedule of lease expense | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Lease expense (1) | $ | $ | $ | $ | ||||||||||||
| Interest expense related to rent in default, associated with unpaid lease payments | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| (1) |
As at September 30, 2026, lease payments of $
Professional fees
| Schedule of professional fees | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Invictus Accounting Group LLP (“Invictus”) (1) | $ | $ | $ | $ | ||||||||||||
| Fabian Vancott (2) | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| (1) | |
| (2) |
| 14 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
Royalty expense
On March 17, 2025, the Company and Alberta Ltd. entered into a security and royalty agreement with Koze (the “Royalty Agreement”) (Note 2), pursuant to which the Company is required to pay a royalty of CAD $0.20 per gram on cannabis product sales, payable at the beginning of the month for the previous month, as additional consideration related to the lease with Formosa. Immediately upon failure to pay the royalty when due, the royalty rate increases to CAD $0.40 per gram sold for the applicable month. As at September 30, 2026, Alberta Ltd. was in default of its payment obligations (see Note 2 and Note 9).
During the three and nine months ended
September 30, 2026, the Company sold
Interest expense
| Schedule of interest expense | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Promissory and convertible notes with Mr. Tal | $ | $ | $ | $ | ||||||||||||
| Promissory and convertible notes with Koze | ||||||||||||||||
| Promissory note with Formosa | ||||||||||||||||
| Rent in default with Formosa | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Imputed interest expense
| Schedule of imputed interest expense | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Promissory and convertible notes with Mr. Tal | $ | $ | $ | $ | ||||||||||||
| Promissory and convertible notes with Koze | ||||||||||||||||
| Promissory note with Formosa | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Other expense
During the nine months ended September 30, 2025,
the Company made a non-cash one-time adjustment of $
Marketing expense included in general and administrative expense
During the three and nine months ended September 30, 2026, the Company
incurred marketing expense of $nil and $nil, respectively (2025 - $
| 15 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
| b) | Amounts due to related parties |
A summary of the Company’s related party liabilities is as follows:
| Schedule of due to related parties | ||||||||
September 30, 2026 | December 31, 2025 | |||||||
| Accounts payable and accrued liabilities | $ | $ | ||||||
| Accrued interest | ||||||||
| Loans payable to related parties | ||||||||
| Royalty payable | ||||||||
| Obligation to issue shares | ||||||||
| Total | $ | $ | ||||||
Accounts payable and accrued liabilities
A summary of accounts payable and accrued liabilities including balances owing to related parties is as follows:
| Schedule of accounts payable and accrued liabilities | ||||||||
September 30, 2026 | December 31, 2025 | |||||||
| Outstanding lease payments to Formosa | $ | $ | ||||||
| Part-time CFO, financial reporting, and bookkeeping services outstanding to Invictus | ||||||||
| Unpaid directors’ fees for 2021 through 2023 to Mr. Rick Orman, a former director of the Company (1) | ||||||||
| Unpaid salary and expense reimbursement to Dominic Colvin, a director of the Company, for his service as Chief Executive Officer from 2019 through 2022 (1) | ||||||||
| Unpaid legal fees to Fabian Vancott | ||||||||
| Total | $ | $ | ||||||
| (1) | See “Claims by Current and Former Directors” in Note 6. |
Accrued interest
A summary of accrued interest payable to related parties is as follows:
| Schedule of accrued interest payable | September 30, 2026 | December 31, 2025 | ||||||
| Promissory and convertible notes with Mr. Tal | $ | $ | ||||||
| Promissory and convertible notes with Koze | ||||||||
| Promissory note with Formosa | ||||||||
| Rent in default with Formosa | ||||||||
| Total | $ | $ | ||||||
| 16 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
Loans payable to related parties
On March 11, 2025, Koze became a related party upon the appointment of its manager as a director of the Company. As a result, the balance owing on promissory notes was reclassified from notes payable to loans payable to related parties during the year ended December 31, 2025.
On August 7, 2025, the Company entered into an agreement (the “Debt Modification”) with Mr. Tal, Koze and Formosa to amend the annual interest rates on all outstanding promissory and convertible notes held by them to 6%, compounding annually. This was deemed to be a substantial modification of the terms of the agreements and was accounted for as an extinguishment of the promissory and convertible notes and recognition of new notes at the new 6% rate. The term to maturity was unchanged. In connection with the issuance of the new notes resulting from the Debt Modification, the Company determined that the market interest rate for similar instruments was 15%. Accordingly, the debt was recorded at a discount to reflect this effective interest rate, with the discount amortized to imputed interest expense over the term of the debt using the effective interest method.
Mr. Tal and Koze are related parties of the Company by virtue of their equity rights. During 2026 the maturity date of all outstanding promissory and convertible notes held by them was extended to December 31, 2026 (the “2026 Debt Amendment”). The stated annual interest rate of 6% and the 15% market rate used to impute interest were unchanged by the 2026 Debt Amendment. Because the notes bear interest below the market rate and are held by shareholders of the Company, the discount arising on initial imputation was recognized as a capital contribution to additional paid-in capital, rather than in the condensed interim consolidated statements of operations and comprehensive income (loss).
A summary of the carrying amounts on the loans payable to related parties is as follows:
| Schedule of outstanding principal | ||||||||
September 30, 2026 | December 31, 2025 | |||||||
| PLC International Investments Inc. (“PLC”) (a) | $ | $ | ||||||
| Koze Lucky Tackle Box Management, LLC (“LTB”) (b) | ||||||||
| Koze A (c) | ||||||||
| Koze B (d) | ||||||||
| Koze C (e) | ||||||||
| Koze convertible note (“Koze CN”) (f) | ||||||||
| Mr. Tal LTB (g) | ||||||||
| Mr. Tal convertible note (“Mr. Tal CN”) (h) | ||||||||
| Formosa (i) | ||||||||
| Total | $ | $ | ||||||
During the three and nine months ended September
30, 2026, Koze made payments of $
As at September 30, 2026, loans payable to
related parties totaled $
| a) | PLC |
Interest-free loan from PLC, a company owned by
Dominic Colvin, a director of the Company. At September 30, 2026, the loan payable was $
| 17 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
| b) | Koze LTB |
On November 22, 2023, the Company entered into
promissory notes of $
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
As a result of the 2026 Debt Amendment, a discounting
effect of $
At September 30, 2026, the carrying value of the
note was $
| c) | Koze A |
On May 25, 2023, the Company entered into a promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund certain documented expenses.
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
As a result of the 2026 Debt Amendment, a discounting
effect of $
During the three and nine months ended September
30, 2026, the Company had $
At September 30, 2026, the carrying value of the
note was $
| d) | Koze B |
On May 25, 2023, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund the Company for certain documented expenses.
| 18 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
As a result of the 2026 Debt Amendment, a discounting
effect of $
During the three and nine months ended September
30, 2026, the Company had $
At September 30, 2026, the carrying value of the
note was $
| e) | Koze C |
On February 8, 2024, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly.
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
As a result of the 2026 Debt Amendment, a discounting
effect of $
At September 30, 2026, the carrying value of the
note was $
| f) | Koze CN |
The Company has a convertible note with Koze,
bearing annual interest at 24%. As a result of the Debt Modification, principal and accrued interest outstanding related to the note as
at August 7, 2025 of $
As a result of the 2026 Debt Amendment, a discounting
effect of $
At September 30, 2026, the carrying value of the
note was $
| g) | Mr. Tal LTB |
On November 22, 2023, the Company entered into
a promissory note of $
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
| 19 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
As a result of the 2026 Debt Amendment, a discounting
effect of $
During the three and nine months ended September
30, 2026, the Company made repayments of $
At September 30, 2026, the carrying value of the
note was $
| h) | Mr. Tal CN |
The Company had a convertible note with Mr. Tal, bearing annual interest at 24%.
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
As a result of the 2026 Debt Amendment, a discounting
effect of $
At September 30, 2026, the carrying value of the
note was $
| i) | Formosa |
On January 1, 2025, the Company entered into a
promissory note with Formosa in the amount of $
As a result of the Debt Modification, principal
and accrued interest outstanding related to the note as at August 7, 2025 of $
At September 30, 2026, the carrying value of the
note was $
The Company has not made payments when due under the note, which is an event of default that gives Formosa the right, at its option, to accelerate repayment. Formosa has not exercised this right as at the date of these financial statements.
A summary of the accrued interest of the Company’s liabilities to related parties is as follows:
| Schedule of accrued interest to related parties | ||||||||
September 30, 2026 | December 31, 2025 | |||||||
| Koze LTB | $ | $ | ||||||
| Koze A | ||||||||
| Koze B | ||||||||
| Koze C | ||||||||
| Koze CN | ||||||||
| Mr. Tal LTB | ||||||||
| Mr. Tal CN | ||||||||
| Formosa | ||||||||
| Formosa - outstanding lease payments | ||||||||
| Total | $ | $ | ||||||
| 20 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
A summary of the interest expense related to the Company’s loans payable to related parties is as follows:
| Schedule of interest expense related parties | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Koze LTB | $ | $ | $ | $ | ||||||||||||
| Koze A | ||||||||||||||||
| Koze B | ||||||||||||||||
| Koze C | ||||||||||||||||
| Koze CN | ||||||||||||||||
| Mr. Tal LTB | ||||||||||||||||
| Mr. Tal CN | ||||||||||||||||
| Formosa | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
A summary of the imputed interest expense related to the Company’s loans payable to related parties is as follows:
| Schedule of imputed interest expense related parties | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Koze LTB | $ | $ | $ | $ | ||||||||||||
| Koze A | ||||||||||||||||
| Koze B | ||||||||||||||||
| Koze C | ||||||||||||||||
| Koze CN | ||||||||||||||||
| Mr. Tal LTB | ||||||||||||||||
| Mr. Tal CN | ||||||||||||||||
| Formosa | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Royalty payable
Pursuant to the Royalty Agreement, as at September
30, 2026, the royalty amount payable to Koze was $
| 21 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
Obligation to issue shares
As at September 30, 2026, the Company has an obligation to issue shares to Mr. Tal and Koze in equal proportions as part of the LTB transaction. The obligation is measured by reference to 454,231,075 common shares at the closing price of the Company’s common shares at the reporting date and was valued at $908,462 (December 31, 2025 - $2,166,681). All 100,000 authorized shares of Series C preferred stock are issued and outstanding. Any portion of the obligation required to be settled in Series C preferred shares cannot be settled until the Company’s certificate of incorporation is amended to increase the authorized Series C preferred stock, which requires stockholder approval. No such amendment has been approved or filed as of the date of these financial statements. Because a sufficient number of authorized and unissued shares is not available, the obligation is recognized as a liability and measured at fair value at each reporting date.
Deferred revenue
As at September 30, 2026, the Company had deferred
revenue of $
NOTE 6 – COMMITMENTS, CONTINGENCIES AND LEGAL MATTERS
As at September 30, 2026, the Company has outstanding borrowings under various loan agreements with multiple lenders, most of which are in default. Certain borrowings are secured by the Company’s assets, including equipment and receivables. In the event of default, lenders may have the right to seize collateralized assets.
Steven Barber
As part of the Company’s acquisition of Alternative Medical Solutions Inc. (“AMS”) in 2018, the Company is working with legal counsel to determine whether it has claims against Steven Barber arising from his alleged default under the consulting agreement entered into in connection with the acquisition (the “Consulting Agreement”). In January 2020, the Company received correspondence from counsel for Mr. Barber demanding payment of amounts purportedly due under the Consulting Agreement. The Company has reviewed whether Mr. Barber performed under the terms of the Consulting Agreement and has identified concerns.
No decision on whether to proceed on these
matters has been reached as at the date of these financial statements, but the Company does not believe that these matters present
a probability of material loss in excess of the amounts recorded, and no additional loss contingency has been recognized. As at
September 30, 2026, the Company has an outstanding payable of $
Deloitte LLP
On July 18, 2024, Deloitte filed a civil
claim in the Alberta Court of Justice alleging a breach of contract. Deloitte was engaged by the Company to assist with fiscal year
2022 finance backfill and diagnostic services and, in accordance with a signed engagement letter dated August 29, 2022, performed
those professional services. Deloitte pleads that it discharged its responsibilities and delivered its invoices to the Company. The
Company acknowledged the satisfactory completion of the services and the amounts billed, but made no further payment as agreed other
than an installment payment on April 18, 2024. Deloitte is seeking recovery of the amount owed. As at September 30, 2026, the amount
payable for services from Deloitte included in accounts payable and accrued liabilities was $
| 22 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 5 - RELATED PARTY TRANSACTIONS (continued)
Former Executives
Former executives John Cassels and Andrew Steedman
(collectively, the “plaintiffs”) have filed a lawsuit against the Company alleging wrongful termination, related misconduct,
and unpaid compensation. The plaintiffs seek CAD $3 million in compensatory damages and an additional CAD $3 million in punitive damages.
As at September 30, 2026, the Company maintains an accrual of approximately CAD $
Astor Street LLC
The Company issued two promissory notes to Astor
Street LLC in January 2021 and granted Astor Street LLC a security interest in all of the Company’s present and after-acquired assets.
Astor Street LLC commenced a claim to recover amounts owing of CAD $312,303 in April 2022 and obtained a default judgment of CAD $
Claims by Current and Former Directors
Dominic Colvin, a director of the Company, has
disputed the amount recorded in respect of unpaid salary and expense reimbursement for his service as Chief Executive Officer during the
years 2019 through 2022 and is asserting a claim for $1,679,060. The Company is reviewing the claim and discussions with Mr. Colvin are
ongoing. No resolution has been reached as at the date of these financial statements. As at September 30, 2026, the Company has recorded
$
Rick Orman, a former director of the Company,
has commenced an action against the Company in the Alberta Court of King’s Bench seeking approximately CAD $840,000 ($592,000),
plus interest, for alleged unpaid accrued compensation and benefits up to his resignation from the board on January 1, 2026. The statement
of claim has not been served on the Company. As at September 30, 2026, the Company has recorded $
| 23 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 7 - SEGMENT REPORTING
The Company operates as a single reportable operating segment. The Company's CODM is its Chief Executive Officer (“CEO”), who reviews financial information presented on a consolidated basis. The CODM uses revenue, cost of goods sold, consolidated operating margin and net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the rate at which the Company seeks to grow its operating profit margin and the allocation of budget between cost of goods sold, professional fees, and general and administrative expenses.
The following table presents selected financial information with respect to the Company’s single operating segment for the three and nine months ended September 30, 2026 and 2025:
| Schedule of single operating segment | ||||||||||||||||
| Three months ended September 30 | Nine months ended September 30 | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||
| Cost of goods sold | ||||||||||||||||
| Gross loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Professional fees | ||||||||||||||||
| Royalty expense | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other segment items | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
NOTE 8 - SIGNIFICANT EVENTS DURING THE PERIOD
On February 3, 2026, the Company entered into an agreement to settle outstanding notes payable with an aggregate principal balance of $50,000 and related accrued interest of $17,034 through the issuance of 30,188,500 shares of common stock. As at March 31, 2026, the carrying value of the notes, including accrued interest, was remeasured to $129,811. The resulting increase in carrying value was recognized as a finance charge and included in interest expense.
On June 18, 2026, the Company issued the 30,188,500 common shares pursuant to the settlement agreement. The shares had a fair value of $75,471, based on the closing market price of $0.0025 per share on the settlement date. The shares were issued in full satisfaction of the debt obligation, which had a carrying value of $132,516, including accrued interest, immediately prior to settlement. Accordingly, the Company recognized the difference between the carrying amount and the settlement amount as a recovery of interest expense of $57,045.
During the three and nine months ended September 30, 2026, the Company recognized a gain of $181,693 and $1,258,219, respectively (2025 - $168,355 and $2,095,299, respectively) on the change in the fair value of the obligation to issue shares to Mr. Tal and Koze (Note 5).
The terms of the related party notes, including the 2026 Debt Amendment, are described in Note 5.
| 24 |
|
CANNAPHARMARX, INC. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (in United States dollars) |
NOTE 9 – SUBSEQUENT EVENTS
The Company has evaluated subsequent events through November 16, 2026, the date these condensed interim consolidated financial statements were issued.
In October 2026, the Company sold 400,000 grams of cannabis product to a related party for CAD 680,000.
On November 5, 2026, the Board of Directors, with the interested director abstaining, approved an extension of the forbearance period (Note 2) to December 31, 2026, and an extension of the maturity of the Mr. Tal and Koze LTB-related notes (Note 5b and 5g) to December 31, 2027. These extensions are documented in an Amendment and Extension to Forbearance Agreement among Formosa, 2323414 Alberta Ltd., the Company, and Koze, and an Amendment to the Amended and Restated Secured Promissory Notes among the Company, Koze, and Mr. Tal, each dated effective October 31, 2026. Under the forbearance amendment, Formosa and Koze agreed to forbear through December 31, 2026 from exercising any rights or remedies arising from defaults that existed as of October 31, 2026. The Company and Mr. Tal also executed a Side Letter Termination and Cancellation Agreement, dated effective October 31, 2026, terminating the Side Letter dated January 18, 2024 under which Mr. Tal held rights to appoint, remove or replace three members of the Company’s Board of Directors.
On November 5, 2026, the Board also approved the issuance of 2,500,000 common shares to a noteholder in settlement of a dispute, and waived the return of 625,000 common shares from another shareholder. The shares had not been issued as at the date of these financial statements.
| 25 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the Company’s financial condition and results of operations as at and for the three and nine months ended September 30, 2026 and 2025 should be read together with the Company’s financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and related footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2025.
We caution readers regarding certain forward-looking statements in the following discussion and elsewhere in this Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward-looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. Except as required by law, we disclaim any obligation to update forward-looking statements.
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes a number of “forward-looking statements” including statements concerning anticipated financial results and developments of our operations in future periods that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2026, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements. These risks and factors include, by way of example and without limitation:
| · | risks associated with the Company's history of losses and need for additional financing, | |
| · | risks associated with increased costs affecting its financial condition, | |
| · | risks associated with uninsured risks, | |
| · | risks associated with governmental and environmental regulations, | |
| · | risks associated with future legislation regarding the cannabis industry and climate change, | |
| · | risks associated with cybersecurity and cyber-attacks, | |
| · | risks associated with legal matters and claims against the Company, | |
| · | risks related to economic conditions, | |
| · | risks related to our ability to manage growth, | |
| · | risks related to our dependence on key personnel, | |
| · | risks related to our SEC filing history, and | |
| · | risks related to our securities. |
| 26 |
This list is not exhaustive of the factors that may affect the Company’s forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Except as required by law, the Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. The Company qualifies all the forward-looking statements contained in this Quarterly Report on Form 10-Q by the foregoing cautionary statements.
Readers are urged to carefully review and consider the various disclosures made by us in this Report and in our other reports filed with the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.
OVERVIEW AND HISTORY
As used in this Quarterly Report on Form 10-Q, unless otherwise indicated, the terms “CannaPharmaRX,” the “Company,” “we,” “us,” and “our” refer to CannaPharmaRX, Inc. and our wholly owned subsidiaries. Unless otherwise specified, all dollar amounts are expressed in United States dollars (“USD”). We specialize in the acquisition, development, and operation of cannabis cultivation facilities in Canada. We were originally incorporated in Colorado in August 1998 as Network Acquisitions, Inc. In October 2014, we changed our legal name to CannaPharmaRx, Inc. We currently focus on producing high-quality medical cannabis and craft cannabis products. Our principal executive office is located at 4439 Township Rd 304, Mountain View County, Alberta, Canada T0M 0R0. Our expansion plans are subject to obtaining additional financing; we do not currently have sufficient cash resources to fund ongoing operations.
On January 1, 2022, we entered into a lease for the use of a 55,000 square foot facility located in Cremona, Alberta, Canada (the “Facility”). The lease was amended and restated effective January 1, 2025 for a term of seventeen years expiring December 31, 2041. During 2022, we recommissioned the Facility into an indoor cannabis farm with 10 growing rooms and one drying and packing room. The Facility now has six growing rooms and one drying and packing room in operation and the Company plans to increase capacity over the next one to two years to open a second drying and packing room and to operate all 10 growing rooms.
We received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency on December 22, 2022 and commenced cannabis production during the year ended December 31, 2023. Our common shares are traded on the OTC Pink Sheets under the trading symbol “CPMD.”
Growth strategy
We plan to grow by increasing capacity at the Facility to support cannabis sales in European markets, with a focus on Germany and Israel. To support this initiative, we intend to expand operations at the Facility from six active growing rooms to all 10 growing rooms over the next one to two years, open a second drying and packing room, build and develop a sales network in Germany and Israel, and apply for European Union Good Manufacturing Practices (“EU-GMP”) certification. Currently, we are required to send our cannabis to a third-party European intermediary for packaging in compliance with EU-GMP standards. Once certified, we expect to eliminate this step and ship directly to countries within the European Union (“EU”), reducing overall costs and shipping times.
To facilitate our growth strategy, on November 22, 2023, we entered into an agreement with LTB Management, LLC (“LTB”) in support of building and developing a sales network in the EU and obtaining access to LTB’s e-commerce technology related to online sales of cannabis in the EU. Under this agreement, we obtained 100 Class B units of LTB in exchange for 27,224,962 share purchase warrants, each entitling the holders to purchase one common share at $0.02 per share until November 22, 2028; $3,000,000 in promissory notes payable to the LTB; and 100,000 Series C preferred shares of our company. Contingent consideration included a quarterly true-up of LTB’s preferred share proportional ownership to 33% of the outstanding shares of our common shares, and an earn out whereby LTB can earn up to an additional 12% pro-rata preferred share proportional ownership (which, if earned, will result in the true-up increasing by the pro-rata preferred share proportional ownership earned) based on our reaching a threshold of $2,500,000 in annual revenue (pro-rated) at any time within 24 months of the agreement date. The earn-out period expired on November 22, 2025. As at September 30, 2026, the Company has an obligation to issue shares to Mr. Tal and Koze under the true-up, valued at $908,462 (see Note 5 of the condensed interim consolidated financial statements). As of December 31, 2025, management concluded the investment was fully impaired and recognized an impairment loss of $4,518,127.
| 27 |
OUR PRODUCTS
Cannabis Products
We produce and sell dried cannabis flower, which we package for sale as dried flower, trim, and shake. We market dried flower primarily for medicinal use. Dried flower remains a core product category across global cannabis markets, and we therefore maintain a strong focus on consistent, high-quality cultivation.
Going Concern
Substantial doubt exists as to our ability to continue as a going concern based on the fact that we do not have adequate working capital to finance our day-to-day operations. For the three and nine months ended September 30, 2026, we reported $137,705 and $1,041,385, respectively (2025 - $656,606 and $1,223,533, respectively) in revenue. As at September 30, 2026, we had cash of $32,037, a working capital deficiency of $30,929,128 and an accumulated deficit of $113,961,237. Additionally, for the nine months ended September 30, 2026, we used $537,675 (2025 - $1,850,544) of cash in operating activities.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management plans to address this uncertainty by seeking additional capital in the near term, primarily through equity issuances or other financing instruments. Given the Company's status as a penny stock issuer on the OTC Markets, its constrained liquidity and solvency position, and the limited availability of third-party financing, management expects that a significant portion of any additional funding will likely need to come from related parties. There can be no assurance that the Company will complete additional financings or collaboration transactions, or that any financing will be available on commercially reasonable terms or in amounts sufficient to meet its obligations and support its business plan. If the Company does not obtain additional financing on a timely basis, it may be required to scale back or cease operations. Any issuance of additional equity securities could materially dilute existing shareholders. In addition, pending litigation and other legal proceedings could adversely affect the Company’s liquidity, results of operations, and ability to continue as a going concern if resolved unfavorably.
On March 17, 2025, the Company and its subsidiary, 2323414 Alberta Ltd. (“Alberta Ltd.”), which conducts the Company’s principal business activities, including the cultivation, processing, and distribution of cannabis, entered into a security and royalty agreement with Koze Investments LLC (“Koze”), a California limited liability company engaged in financing and investment activities. Koze has been considered a related party since March 11, 2025, the date on which its manager, Elliot Zemel, was appointed as a director of the Company. Under the agreement, the Company is required to pay a royalty on cannabis product sales from the prior month, with the applicable rate increasing if royalty payments are not made on time. The agreement provides that a default occurs if Alberta Ltd. fails to make royalty or lease payments for three consecutive months or for any four months within a rolling six-month period. As collateral, the Company granted Koze a security interest in its entire ownership interest in Alberta Ltd., which will remain in place until all obligations are fully satisfied. As at September 30, 2026, Alberta Ltd. was in default of its payment obligations, and Koze agreed to forbear from exercising its rights over that ownership interest until August 31, 2026. The forbearance period expired on August 31, 2026. See Note 2 and Note 9 to the condensed interim consolidated financial statements. The Company also incurred royalty expense under the agreement and recorded a related liability in royalty payable as at September 30, 2026.
| 28 |
RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
Revenue
During the three months ended September 30, 2026 and 2025, the Company reported revenue of $137,705 and $656,606, respectively. The decrease primarily reflects lower sales volumes in the current period, with no sales to Cantek in the current quarter, as discussed under “Related party transactions.”
Cost of Goods Sold
During the three months ended September 30, 2026 and 2025, the Company reported cost of goods sold of $415,487 and $1,030,313, respectively. The decrease was primarily due to lower sales volumes and lower inventory impairment charges in the current period. Included in cost of goods sold for the three months ended September 30, 2026 and 2025 are losses on the impairment of inventory of $284,632 and $393,796, respectively, primarily based on factors including expected yield of work-in-progress inventory and corresponding market prices.
Gross Loss
During the three months ended September 30, 2026 and 2025, the Company reported a gross loss of $277,782 and $373,707, respectively. The decrease in gross loss primarily reflects the decrease in cost of goods sold, including lower inventory impairment charges, which more than offset the decrease in revenue in the current period.
Operating Expenses
A summary of the Company’s operating expenses is as follows:
| Three months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| General and administrative | $ | 159,445 | $ | 211,737 | ||||
| Professional fees | 66,193 | 115,990 | ||||||
| Royalty expense | 29,523 | 234,212 | ||||||
| $ | 255,161 | $ | 561,939 | |||||
During the three months ended September 30, 2026 and 2025, the Company’s operating expenses consisted primarily of general and administrative expenses, professional fees associated with the costs for services or employees in finance, accounting, sales, administrative activities and the compliance of a public company, and royalty expense. Overall operating expenses for the three months ended September 30, 2026 were $255,161 compared to operating expenses of $561,939 in the prior year comparable period, a decrease of $306,778. The decrease is primarily attributable to the following:
| · | A $204,689 decrease in royalty expense, reflecting lower grams sold in the current period than in the prior-year comparable period under the Koze agreement entered into on March 17, 2025. |
| · | A $49,797 decrease in professional fees, primarily reflecting lower accounting and legal fees in the current period. |
| · | A $52,292 decrease in general and administrative expenses, primarily reflecting lower advertising and marketing, travel and property tax costs in the current period. |
| 29 |
Other income (expenses)
A summary of the Company’s other income and expenses is as follows:
| Three months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Change in the fair value of derivative conversion feature | $ | 1,728,677 | $ | 7,296 | ||||
| Change in the fair value of obligation to issue shares | 181,693 | 168,355 | ||||||
| Foreign exchange gain (loss) | 637 | (24,243 | ) | |||||
| Interest expense | (458,291 | ) | (506,331 | ) | ||||
| Imputed interest expense | (274,357 | ) | (187,242 | ) | ||||
| $ | 1,178,359 | $ | (542,165 | ) | ||||
Other income totaled $1,178,359 for the three months ended September 30, 2026, compared with other expenses of $542,165 in the comparable 2025 period, primarily due to the following:
| · | Change in the fair value of derivative conversion feature arising from variably priced convertible notes was a gain of $1,728,677 compared to a gain of $7,296 in the prior year comparable period. The primary drivers of these fair value changes were changes in the Company’s share price and peer-based expected volatility as the Company’s common shares trade infrequently on the OTC Markets, the remaining term to expiration of the convertible notes and the conversion feature's exercise price. |
| · | Change in the fair value of obligation to issue shares was a gain of $181,693 compared to a gain of $168,355 in the 2025 comparable period resulting from remeasurement of the obligation to issue shares. |
The increase in other income was partially offset by the following:
| · | A $87,115 increase in imputed interest expense due to debt modification of certain loans to related parties, which resulted in a remeasurement of the liabilities and recognition of additional imputed interest expense. |
| · | A $48,040 decrease in interest expense, which partially offset the increase in imputed interest expense, is primarily attributable to a reduction in the interest rate for certain loans to related parties, pursuant to a debt modification agreement entered into by the Company with those related parties. |
Net Income (Loss)
As a result of the foregoing, during the three months ended September 30, 2026, the Company recorded net income of $645,416 or $0.00 per share basic and $(0.00) diluted compared to a net loss of $1,477,811 or $(0.00) per share in the 2025 comparable quarter. The quarter’s net income reflects non-cash fair value gains of $1,728,677 on derivative conversion features and $181,693 on the obligation to issue shares, notwithstanding an operating loss of $532,943. These gains did not provide cash to fund operations.
RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
Revenue
During the nine months ended September 30, 2026 and 2025, the Company reported revenue of $1,041,385 and $1,223,533, respectively. The decrease primarily reflects lower sales volumes in the current period. As discussed under “Related party transactions,” related-party revenue from Cantek was $903,680 in 2026 compared with $231,608 in the prior-year comparable period.
| 30 |
Cost of Goods Sold
During the nine months ended September 30, 2026 and 2025, the Company reported cost of goods sold of $1,734,527 and $2,591,451 respectively. The decrease was primarily due to lower sales volumes and lower inventory impairment charges in the current period. Included in cost of goods sold for the nine months ended September 30, 2026 and 2025 are losses on the impairment of inventory of $864,567 and $1,310,393, respectively, primarily based on factors including expected yield of work-in-progress inventory and corresponding market prices.
Gross Loss
During the nine months ended September 30, 2026 and 2025, the Company reported a gross loss of $693,142 and $1,367,918, respectively. The decrease in gross loss primarily reflects the decrease in cost of goods sold, including lower inventory impairment charges, which more than offset the decrease in revenue in the current period.
Operating Expenses
A summary of the Company’s operating expenses is as follows:
| Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| General and administrative | $ | 410,537 | $ | 455,936 | ||||
| Professional fees | 265,820 | 340,546 | ||||||
| Royalty expense | 224,618 | 289,811 | ||||||
| $ | 900,975 | $ | 1,086,293 | |||||
During the nine months ended September 30, 2026 and 2025, the Company’s operating expenses consisted primarily of general and administrative expenses, professional fees associated with the costs for services or employees in finance, accounting, sales, administrative activities and the compliance of a public company, and royalty expense. Overall operating expenses for the nine months ended September 30, 2026 were $900,975 compared to operating expenses of $1,086,293 in the prior year comparable period, a decrease of $185,318. The decrease is primarily attributable to the following:
| · | A $65,193 decrease in royalty expense, reflecting lower grams sold in the current period than in the prior-year comparable period under the Koze agreement entered into on March 17, 2025. |
| · | A $74,726 decrease in professional fees, primarily reflecting lower accounting and legal fees in the current period. |
| · | A $45,399 decrease in general and administrative expenses, primarily reflecting lower advertising and marketing and travel costs, partially offset by higher selling and distribution costs. |
Other income (expenses)
A summary of the Company’s other income and expenses is as follows:
| Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Change in the fair value of derivative conversion feature | $ | 929,977 | $ | 602,569 | ||||
| Change in the fair value of obligation to issue shares | 1,258,219 | 2,095,299 | ||||||
| Foreign exchange gain (loss) | (77,448 | ) | 71,084 | |||||
| Interest expense | (1,282,916 | ) | (1,779,362 | ) | ||||
| Imputed interest expense | (879,362 | ) | (187,242 | ) | ||||
| Other expense | – | (1,930,000 | ) | |||||
| $ | (51,530 | ) | $ | (1,127,652 | ) | |||
| 31 |
Other expenses totaled $51,530 for the nine months ended September 30, 2026 compared with $1,127,652 in the comparable 2025 period. The decrease was primarily due to the following:
| · | Change in the fair value of derivative conversion feature arising from variably priced convertible notes was a gain of $929,977 compared to a gain of $602,569 in the prior year comparable period. The primary drivers of these fair value changes were changes in the Company’s share price and peer-based expected volatility as the Company’s common shares trade infrequently on the OTC Markets, the remaining term to expiration of the convertible notes and the conversion feature's exercise price. |
| · | A $496,446 decrease in interest expense is primarily attributable to a reduction in the interest rate for certain loans to related parties, pursuant to a debt modification agreement entered into by the Company with those related parties. |
| · | A non-cash one-time adjustment of $1,930,000 in the prior year comparable period was made to lease-related rent expense due to a clarification in the interpretation of the lease terms between management and Formosa, with no comparable charge in the current period. |
The decrease in other expenses was partially offset by the following:
| · | A $692,120 increase in imputed interest expense due to debt modification of certain loans to related parties, which resulted in a remeasurement of the liabilities and recognition of additional imputed interest expense. |
| · | Change in the fair value of obligation to issue shares was a gain of $1,258,219 compared to a gain of $2,095,299 in the 2025 comparable period resulting from remeasurement of the obligation to issue shares. |
Net Loss
As a result of the foregoing, during the nine months ended September 30, 2026, the Company recorded a net loss of $1,645,647 or ($0.00) per share compared to a net loss of $3,581,863 or ($0.01) per share in the 2025 comparable period.
LIQUIDITY AND CAPITAL RESOURCES
As at September 30, 2026, the Company had $32,037 in cash, compared with $1,804 as at December 31, 2025, and a working capital deficiency of $30,929,128 compared with $30,278,570 as at December 31, 2025. During the nine months ended September 30, 2026, the Company’s funding was primarily attributable to advances made by Koze, a related party, directly to the Company’s suppliers. During the three and nine months ended September 30, 2026, Koze made payments of $474,056 and $1,432,492, respectively, directly to the Company’s suppliers. In addition, Koze received $nil and $785,105 respectively directly from customers. These advances and customer collections relate to an ongoing funding arrangement under which Koze funds additional amounts from time to time based on the Company’s operational needs, has no stated limit, and may be discontinued by Koze at any time.
The Company is dependent on Koze to continue funding its operations. As at September 30, 2026, loans payable to related parties totaled $14,382,683, all of which is classified as current. The Koze and Mr. Tal notes mature on December 31, 2026, and Alberta Ltd. is in default of its royalty payment obligations under the security and royalty agreement with Koze. Koze’s forbearance from exercising its rights over the ownership interest expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities.
| 32 |
Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern. Management intends to address these liquidity challenges through debt financings and/or raise additional funding through equity financing to support ongoing operating expenses and working capital needs. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company and therefore, the Company is heavily reliant on funding from related parties. If the Company is unable to secure adequate financing or otherwise successfully implement its plans, it may be required to significantly reduce or curtail its operations, or cease operations entirely. Any issuance of equity securities to raise capital could result in substantial dilution to existing shareholders. Certain borrowings are secured by the Company’s assets, including equipment and receivables. In the event of default, lenders may have the right to seize collateralized assets.
The summary of the Company’s cash flows is as follows:
| Nine months ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash used in operating activities | $ | (537,675 | ) | $ | (1,850,544 | ) | ||
| Cash used in investing activities | (55,706 | ) | – | |||||
| Cash provided by financing activities | 624,069 | 1,849,315 | ||||||
| Effect of exchange rate changes on cash | (455 | ) | – | |||||
| Net change in cash | $ | 30,233 | $ | (1,229 | ) | |||
Cash flows from operating activities
Cash used in operating activities for the nine months ended September 30, 2026 decreased by $1,312,869 compared to the prior year comparable period, primarily due to higher cash paid by related parties directly to suppliers in the current period.
Cash flows from investing activities
Cash used in investing activities for the nine months ended September 30, 2026 was $55,706 compared to $nil in the prior year comparable period, due to purchase of equipment.
Cash flows from financing activities
Cash provided by financing activities for the nine months ended September 30, 2026 was $624,069 compared to $1,849,315 in the prior year comparable period, due to proceeds from related party loans.
Related party transactions
Revenue
During the three and nine months ended September 30, 2026, the Company recognized revenue of $nil and $903,680, respectively (2025 - $nil and $231,608, respectively) from the related party D.N.S. CANTEK 2019 LTD (“Cantek”), an Israeli limited corporation owned 100% by Koze, and for which Mr. Tal serves as a financial advisor.
A summary of the Company’s average selling prices by market is as follows:
| Average Price per Gram (CAD)* | ||||||||
| Market | Premium Batches | Medium Batches | ||||||
| Germany | 2.05 | 1.60 | ||||||
| Israel | 2.00 | 1.60-1.80 | ||||||
| Canada | 2.00 | 1.10-1.50 | ||||||
| Portugal | 1.80-2.00 | 0.80-1.50 | ||||||
* Batches with THC concentrations below 20% are generally sold at lower average prices compared to higher-THC batches.
Lease expense
| 33 |
The Company has a lease with Formosa, which became a related party upon the appointment of its manager, Elliot Zemel, as a director of the Company on March 11, 2025.
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Lease expense (1) | $ | 267,934 | $ | 272,232 | $ | 812,204 | $ | 804,457 | ||||||||
| Interest expense related to rent in default, associated with unpaid lease payments | 177,471 | 145,858 | 508,440 | 435,600 | ||||||||||||
| Total | $ | 445,405 | $ | 418,090 | $ | 1,320,644 | $ | 1,240,057 | ||||||||
| (1) | Lease expense above represents the contractual rent payable under the lease. The lease cost charged to production for the three and nine months ended September 30, 2026 was $260,986 and $791,047, respectively, of which the idle-capacity share is presented in general and administrative expenses and the balance is included in cost of goods sold. |
Professional fees
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Invictus Accounting Group LLP (“Invictus”) (1) | $ | 41,659 | $ | 42,119 | $ | 111,647 | $ | 168,938 | ||||||||
| Fabian Vancott (2) | – | 4,600 | 11,925 | 51,787 | ||||||||||||
| Total | $ | 41,659 | $ | 46,719 | $ | 123,572 | $ | 220,725 | ||||||||
| (1) | Invictus provides part-time CFO, financial reporting, and bookkeeping services to the Company. Mr. Oliver Foeste is the Managing Partner of Invictus. |
| (2) | Anthony Panek who is a partner in Fabian Vancott, is also a director of the Company. |
Royalty expense
On March 17, 2025, the Company and Alberta Ltd. entered into the Royalty Agreement, pursuant to which the Company is required to pay a royalty of CAD $0.20 per gram on cannabis product sales, payable at the beginning of the month for the previous month, as additional consideration related to the lease with Formosa. Immediately upon failure to pay the royalty when due, the royalty rate increases to CAD $0.40 per gram sold for the applicable month. As at September 30, 2026, Alberta Ltd. was in default of its payment obligations, and Koze agreed to forbear from exercising its rights over the ownership interest until August 31, 2026. The forbearance period expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities.
During the three and nine months ended September 30, 2026, the Company sold 102,244 and 773,299 grams of cannabis products, respectively, (2025 - 806,568 and 998,952 grams respectively) and for the three and nine months ended September 30, 2026, the Company incurred a royalty expense of $29,523 and $224,618, respectively (2025 - $234,212 and $289,811, respectively) which is calculated using a royalty rate of CAD $0.40 per gram sold since no royalty payments have been made by the Company
Interest expense
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Promissory and convertible notes with Mr. Tal | $ | 11,734 | $ | 17,016 | $ | 32,402 | $ | 71,154 | ||||||||
| Promissory and convertible notes with Koze | 189,176 | 288,597 | 496,236 | 1,109,554 | ||||||||||||
| Promissory note with Formosa | 31,187 | 26,459 | 87,386 | 75,120 | ||||||||||||
| Rent in default with Formosa | 177,471 | 145,858 | 508,440 | 435,600 | ||||||||||||
| Total | $ | 409,568 | $ | 477,930 | $ | 1,124,464 | $ | 1,691,428 | ||||||||
| 34 |
Imputed interest expense
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Promissory and convertible notes with Mr. Tal | $ | 18,552 | $ | 12,135 | $ | 50,914 | $ | 12,135 | ||||||||
| Promissory and convertible notes with Koze | 204,171 | 145,587 | 683,771 | 145,587 | ||||||||||||
| Promissory note with Formosa | 51,634 | 29,520 | 144,677 | 29,520 | ||||||||||||
| Total | $ | 274,357 | $ | 187,242 | $ | 879,362 | $ | 187,242 | ||||||||
Other expense
During the nine months ended September 30, 2025, the Company made a non-cash one-time adjustment of $1,930,000 to lease-related rent expense due to a clarification in the interpretation of the lease terms for the Facility, which is recorded as other expense.
Amounts due to related parties
September 30, 2026 | December 31, 2025 | |||||||
| Accounts payable and accrued liabilities | $ | 6,121,882 | $ | 5,416,889 | ||||
| Accrued interest | 2,150,400 | 1,352,899 | ||||||
| Loans payable to related parties | 14,382,683 | 13,116,485 | ||||||
| Royalty payable | 513,129 | 305,492 | ||||||
| Liability for right-of-use building | 5,771,851 | 6,034,080 | ||||||
| Obligation to issue shares | 908,462 | 2,166,681 | ||||||
| Total | $ | 29,848,407 | $ | 28,392,526 | ||||
Accounts payable and accrued liabilities
A summary of accounts payable and accrued liabilities including balances owing to related parties is as follows:
September 30, 2026 | December 31, 2025 | |||||||
| Outstanding lease payments to Formosa | $ | 5,041,794 | $ | 4,283,706 | ||||
| Part-time CFO, financial reporting, and bookkeeping services outstanding to Invictus | 101,747 | 146,306 | ||||||
| Unpaid directors’ fees for 2021 through 2023 to Rick Orman, a former director of the Company (1) | 319,279 | 319,279 | ||||||
| Unpaid salary and expense reimbursement to Dominic Colvin, a director of the Company, for his service as Chief Executive Officer from 2019 through 2022 (1) | 533,202 | 551,953 | ||||||
| Unpaid legal fees to Fabian Vancott | 125,860 | 115,645 | ||||||
| Total | $ | 6,121,882 | $ | 5,416,889 | ||||
| (1) | See “Claims by Current and Former Directors” in Note 6 to the condensed interim consolidated financial statements. |
| 35 |
Loans payable to related parties
On August 7, 2025, the Company entered into an agreement (the “Debt Modification”) with Mr. Tal, Koze and Formosa to amend the annual interest rates on all outstanding promissory and convertible notes held by them to 6%, compounding annually. This was deemed to be a substantial modification of the terms of the agreements and was accounted for as an extinguishment of the promissory and convertible notes and recognition of new notes at the new 6% rate. The term to maturity was unchanged. In connection with the issuance of the new notes resulting from the Debt Modification, the Company determined that the market interest rate for similar instruments was 15%. Accordingly, the debt was recorded at a discount to reflect this effective interest rate, with the discount amortized to imputed interest expense over the term of the debt using the effective interest method.
Mr. Tal and Koze are related parties of the Company by virtue of their equity rights. During 2026 the maturity date of all outstanding promissory and convertible notes held by them was extended to December 31, 2026 (the "2026 Debt Amendment"). The stated annual interest rate of 6% and the 15% market rate used to impute interest were unchanged by the 2026 Debt Amendment. Because the notes bear interest below the market rate and are held by shareholders of the Company, the discount arising on initial imputation was recognized as a capital contribution to additional paid-in capital, rather than in the condensed interim consolidated statements of operations and comprehensive income (loss).
A summary of the carrying amounts on the loans payable to related parties is as follows:
September 30, 2026 | December 31, 2025 | |||||||
| PLC International Investments Inc. (“PLC”) (a) | $ | 12,995 | $ | 13,430 | ||||
| Koze Lucky Tackle Box Management, LLC (“LTB”) (b) | 3,136,805 | 3,093,478 | ||||||
| Koze A (c) | 1,797,914 | 1,400,243 | ||||||
| Koze B (d) | 6,282,535 | 5,529,686 | ||||||
| Koze C (e) | 344,845 | 343,701 | ||||||
| Koze convertible note (“Koze CN”) (f) | 131,735 | 131,298 | ||||||
| Mr. Tal LTB (g) | 375,487 | 447,647 | ||||||
| Mr. Tal convertible note (“Mr. Tal CN”) (h) | 305,260 | 306,571 | ||||||
| Formosa (i) | 1,995,107 | 1,850,431 | ||||||
| Total | $ | 14,382,683 | $ | 13,116,485 | ||||
| a) | PLC |
Interest-free loan from PLC, a company owned by Dominic Colvin, a director of the Company.
| b) | Koze LTB |
On November 22, 2023, the Company entered into promissory notes of $2,550,000 with Koze, as part of the LTB transaction, bearing interest at 13% per annum. Originally due on November 22, 2024, the maturity date for this note was extended to December 31, 2025, by agreement with Koze. On March 18, 2026, Mr. Tal and Koze agreed to extend the maturity date of the promissory notes to December 31, 2026.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $2,550,000 and $555,406, respectively, were extinguished. A new note (“Koze LTB”) of $2,978,661 bearing 6% interest, compounding annually, was recognized resulting in a gain of $126,745 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $244,792 was recognized as a capital contribution to additional paid-in capital.
| 36 |
| c) | Koze A |
On May 25, 2023, the Company entered into a promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund certain documented expenses.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $849,278 and $443,339, respectively, were extinguished. A new note (“Koze A”) of $1,134,669 bearing 6% interest, compounding annually, was recognized resulting in a gain of $157,949 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $124,239 was recognized as a capital contribution to additional paid-in capital.
During the three and nine months ended September 30, 2026, the Company had $137,995 and $401,976 in net additions to the promissory note.
| d) | Koze B |
On May 25, 2023, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund the Company for certain documented expenses.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $4,040,474 and $1,366,780, respectively, were extinguished. A new note (“Koze B”) of $4,767,106 bearing 6% interest, compounding annually, was recognized resulting in a gain of $640,148 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $473,849 was recognized as a capital contribution to additional paid-in capital.
During the three and nine months ended September 30, 2026, the Company had $600,568 and $1,731,365 in additions on the promissory note. During the three and nine months ended September 30, 2026, the Company had $nil and $785,105 in repayments on the promissory note.
| e) | Koze C |
On February 8, 2024, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $275,000 and $97,403, respectively, were extinguished. A new note (“Koze C”) of $330,551 bearing 6% interest, compounding annually, was recognized resulting in a gain of $41,852 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $30,562 was recognized as a capital contribution to additional paid-in capital.
| f) | Koze CN |
The Company has a convertible note with Koze, bearing annual interest at 24%. As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $68,555 and $75,714, respectively, were extinguished. A new note, Koze CN, of $126,275 bearing 6% interest, compounding annually, was recognized resulting in a gain of $17,995 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $11,675 was recognized as a capital contribution to additional paid-in capital.
| 37 |
| g) | Mr. Tal LTB |
On November 22, 2023, the Company entered into a promissory note of $450,000 with Mr. Tal as part of the LTB transaction, bearing interest at 13% per annum. Originally due on November 22, 2024, the maturity date for this note was extended to December 31, 2025, by agreement with Mr. Tal. On March 18, 2026, Mr. Tal and Koze agreed to extend the maturity date of the promissory notes to December 31, 2026.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $438,296 and $89,768, respectively, were extinguished. A new note (“Mr. Tal LTB”) of $507,422 bearing 6% interest, compounding annually, was recognized resulting in a gain of $20,641 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $39,888 was recognized as a capital contribution to additional paid-in capital.
During the three and nine months ended September 30, 2026, the Company made repayments of $46,778 and $76,778 on the promissory note and accrued interest.
| h) | Mr. Tal CN |
The Company had a convertible note with Mr. Tal, bearing annual interest at 24%.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $212,555 and $121,427, respectively, were extinguished. A new note, Mr. Tal CN, of $294,850 bearing 6% interest, compounding annually, was recognized resulting in a gain of $39,132 from extinguishment, recorded directly to additional paid-in capital.
As a result of the 2026 Debt Amendment, a discounting effect of $29,435 was recognized as a capital contribution to additional paid-in capital.
| i) | Formosa |
On January 1, 2025, the Company entered into a promissory note with Formosa in the amount of $1,930,000, bearing interest at 5% per annum, with respect to a one-time adjustment made to lease-related rent expense due to a clarification in the interpretation of the lease terms for the Facility.
As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $1,930,000 and $58,098, respectively, were extinguished. A new note of $1,775,707 bearing 6% interest, compounding annually, was recognized resulting in a gain of $212,391 from extinguishment, recorded directly to additional paid-in capital.
A summary of the accrued interest of the Company’s loans payable to related parties is as follows:
September 30, 2026 | December 31, 2025 | |||||||
| Koze LTB | $ | 135,427 | $ | 76,062 | ||||
| Koze A | 72,646 | 31,070 | ||||||
| Koze B | 260,523 | 132,215 | ||||||
| Koze C | 14,888 | 8,394 | ||||||
| Koze CN | 5,687 | 3,207 | ||||||
| Mr. Tal LTB | 16,882 | 11,887 | ||||||
| Mr. Tal CN | 13,184 | 7,488 | ||||||
| Promissory note with Formosa | 132,795 | 45,396 | ||||||
| $ | 652,032 | $ | 315,719 | |||||
| 38 |
A summary of the interest expense related to the Company’s loans payable to related parties is as follows:
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Koze LTB | $ | 46,699 | $ | 58,136 | $ | 135,427 | $ | 222,524 | ||||||||
| Koze A | 29,252 | 62,349 | 72,646 | 153,506 | ||||||||||||
| Koze B | 106,130 | 156,655 | 267,588 | 681,064 | ||||||||||||
| Koze C | 5,134 | 8,818 | 14,888 | 41,595 | ||||||||||||
| Koze CN | 1,961 | 2,639 | 5,687 | 10,865 | ||||||||||||
| Mr. Tal LTB | 7,190 | 9,805 | 19,223 | 38,436 | ||||||||||||
| Mr. Tal CN | 4,544 | 7,211 | 13,179 | 32,718 | ||||||||||||
| Formosa | 31,187 | 26,459 | 87,386 | 75,120 | ||||||||||||
| Total | $ | 232,097 | $ | 332,072 | $ | 616,024 | $ | 1,255,828 | ||||||||
A summary of the imputed interest expense related to the Company’s loans payable to related parties is as follows:
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Koze LTB | $ | 73,123 | $ | 45,258 | $ | 212,056 | $ | 45,258 | ||||||||
| Koze A | 20,913 | 17,836 | 88,861 | 17,836 | ||||||||||||
| Koze B | 99,026 | 75,310 | 350,636 | 75,310 | ||||||||||||
| Koze C | 8,038 | 5,198 | 23,312 | 5,198 | ||||||||||||
| Koze CN | 3,071 | 1,985 | 8,906 | 1,985 | ||||||||||||
| Mr. Tal LTB | 11,436 | 7,501 | 30,278 | 7,501 | ||||||||||||
| Mr. Tal CN | 7,116 | 4,634 | 20,636 | 4,634 | ||||||||||||
| Formosa | 51,634 | 29,520 | 144,677 | 29,520 | ||||||||||||
| Total | $ | 274,357 | $ | 187,242 | $ | 879,362 | $ | 187,242 | ||||||||
Royalty payable
Pursuant to the Royalty Agreement, as at September 30, 2026, the royalty amount payable to Koze was $513,129 (CAD $728,047) (December 31, 2025 - $305,492 (CAD $418,707)).
Obligation to issue shares
As at September 30, 2026, the Company has an obligation to issue shares to Mr. Tal and Koze in equal proportions as part of the LTB transaction. The obligation is measured by reference to 454,231,075 common shares at the closing price of the Company’s common shares at the reporting date and was valued at $908,462 (December 31, 2025 - $2,166,681). All 100,000 authorized shares of Series C preferred stock are issued and outstanding. Any portion of the obligation required to be settled in Series C preferred shares cannot be settled until the Company’s certificate of incorporation is amended to increase the authorized Series C preferred stock, which requires stockholder approval. No such amendment has been approved or filed as of the date of these financial statements. Because a sufficient number of authorized and unissued shares is not available, the obligation is recognized as a liability and measured at fair value at each reporting date.
Liability for right-of-use building
On March 11, 2025, Formosa became a related party upon the appointment of its manager as a director of the Company.
As at September 30, 2026, the liability for right-of-use building was $5,771,851 (December 31, 2025 - $6,034,080).
| 39 |
Under the terms of the agreement, a default occurs if Alberta Ltd. fails to make such payments or lease payments for three consecutive months or for any four months within any rolling six-month period. As collateral for the obligations under the agreement, the Company granted Koze a security interest in all of its ownership interest in Alberta Ltd. The security interest will remain in place until all obligations are fully satisfied. As at September 30, 2026, Alberta Ltd. has failed to make the payments under the agreement and Koze agreed to forbear from exercising its right of ownership interest in Alberta Ltd. until August 31, 2026 (Note 2). The forbearance period expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities. During the three and nine months ended September 30, 2026, the Company recognized interest expense related to rent in default of $177,471 and $508,440, respectively, associated with unpaid lease payments (2025 - $145,858 and $435,600, respectively). As at September 30, 2026, accrued interest related to rent in default was $1,498,368 (December 31, 2025 - $1,037,180).
As at September 30, 2026, lease payments of $5,041,794 were outstanding, which is an event of default under the lease. On an event of default, Formosa may, at its option and by notice, require immediate payment of the current month’s rent, the rent for the following three months and all amounts outstanding. No such notice has been given as at the date of this report.
Deferred revenue
As at September 30, 2026, the Company had deferred revenue of $36,298 (December 31, 2025 - $260,561) related to transactions with related parties. The deferred revenue balance represents consideration received in advance for products to be delivered.
Critical accounting estimates
The Company’s financial statements and accompanying notes have been prepared in accordance with US GAAP. The preparation of these financial statements requires management to make estimates, judgments, and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management.
In preparing these financial statements, the Company is exposed to the same sources of estimation uncertainty as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
The Company is classified as a smaller reporting company and is not required to provide the information under this item pursuant to Regulation S-K.
| 40 |
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and procedures
Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report.
These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our CEO and CFO to allow timely decisions regarding required disclosure.
Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were not effective as at September 30, 2026, due to the material weakness in internal control over financial reporting described below.
Inherent limitations
Our management, including our CEO and CFO, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.
Changes in internal control over financial reporting
During the quarter ended September 30, 2026, management continued its efforts to improve the Company's internal control over financial reporting and to remediate the material weakness described below. Remediation activities undertaken during the quarter included enhanced review procedures over significant and unusual transactions, continued involvement of external accounting professionals in the preparation and review of the Company's financial reporting, and continued efforts to improve the maintenance and retention of supporting documentation for significant transactions and account balances.
These remediation efforts are ongoing and have not yet operated for a sufficient period to allow management to conclude that the material weakness has been remediated. Other than the remediation activities described above, there were no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2026 that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
| 41 |
Update on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Those rules define internal control over financial reporting as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and include those policies and procedures that:
| · | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; |
| · | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and the receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and |
| · | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the Company’s assets that could have a material effect on the financial statements. |
Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management assessed the effectiveness of our internal control over financial reporting as at September 30, 2026. In making this assessment, management used the criteria set forth in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
Based on its assessment, management has concluded that as at September 30, 2026, our disclosure controls and procedures and internal control over financial reporting were not effective and that a material weakness existed in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Management has identified deficiencies in operating effectiveness that, in combination, represent a material weakness in internal control over financial reporting as follows:
| · | Due to management and staff turnover in the prior years, accurate information and records were not consistently maintained within our records and there were instances where documentation to support certain transactions was difficult to obtain or unobtainable. These deficiencies represent a material weakness in our internal control over financial reporting. |
Because of the material weakness identified, management has concluded that its internal control over financial reporting was not effective as at September 30, 2026. We are in the process of developing and implementing remediation plans to address the material weakness described above.
| 42 |
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Steven Barber
As part of the Company’s acquisition of Alternative Medical Solutions Inc. (“AMS”) in 2018, the Company is working with legal counsel to determine whether it has claims against Steven Barber arising from his alleged default under the consulting agreement entered into in connection with the acquisition (the “Consulting Agreement”). In January 2020, the Company received correspondence from counsel for Mr. Barber demanding payment of amounts purportedly due under the Consulting Agreement. The Company has reviewed whether Mr. Barber performed under the terms of the Consulting Agreement and has identified concerns.
No decision on whether to proceed on these matters has been reached as at the date of this Report, but the Company does not believe that these matters present a probability of material loss in excess of the amounts recorded, and no additional loss contingency has been recognized. As at September 30, 2026, the Company has an outstanding payable of $549,780 included in accounts payable and accrued liabilities (December 31, 2025 - $549,780).
Deloitte LLP
On July 18, 2024, Deloitte filed a civil claim in the Alberta Court of Justice alleging a breach of contract. Deloitte was engaged by the Company to assist with fiscal year 2022 finance backfill and diagnostic services and, in accordance with a signed engagement letter dated August 29, 2022, performed those professional services. Deloitte pleads that it discharged its responsibilities and delivered its invoices to the Company. The Company acknowledged the satisfactory completion of the services and the amounts billed, but made no further payment as agreed other than an installment payment on April 18, 2024. Deloitte is seeking recovery of the amount owed. As at September 30, 2026, the amount payable for services from Deloitte included in accounts payable and accrued liabilities was $33,357 (December 31, 2025 - $34,530).
Former Executives
Former executives John Cassels and Andrew Steedman (collectively, the “plaintiffs”) have filed a lawsuit against the Company alleging wrongful termination, related misconduct, and unpaid compensation. The plaintiffs seek CAD $3 million in compensatory damages and an additional CAD $3 million in punitive damages. As at September 30, 2026, the Company maintains an accrual of approximately CAD $1,276,811 ($899,923) for unpaid salaries owed to the plaintiffs for services rendered from April 2019 through June 2023. The Company was noted in default in March 2025. In February 2026, the Company applied to set aside the default, and in May 2026 the plaintiffs filed a cross-application for default judgment. Both applications are to be heard in special chambers. No additional loss contingency has been recorded because the outcome of the applications and the ultimate amount of any loss cannot be reasonably estimated at this time.
Astor Street LLC
The Company issued two promissory notes to Astor Street LLC in January 2021 and granted Astor Street LLC a security interest in all of the Company’s present and after-acquired assets. Astor Street LLC commenced a claim to recover amounts owing of CAD $312,303 in April 2022 and obtained a default judgment of CAD $314,273 in March 2023. On September 30, 2025, Astor Street LLC took steps to seize assets belonging to the Company. The Company is assessing the validity of the claim and default judgment and whether a negotiated resolution is necessary. As at September 30, 2026, amounts payable on the promissory notes to Astor Street LLC included in notes payable were $211,446 (CAD $300,000) (December 31, 2025 - $218,882 (CAD $300,000)).
| 43 |
Claims by Current and Former Directors
Dominic Colvin, a director of the Company, has disputed the amount recorded in respect of unpaid salary and expense reimbursement for his service as Chief Executive Officer during the years 2019 through 2022 and is asserting a claim for $1,679,060. The Company is reviewing the claim and discussions with Mr. Colvin are ongoing. No resolution has been reached as at the date of this Report. As at September 30, 2026, the Company has recorded $533,202 (CAD $756,507) in accounts payable and accrued liabilities in respect of these amounts (December 31, 2025 - $551,953 (CAD $756,507)).
Rick Orman, a former director of the Company, has commenced an action against the Company in the Alberta Court of King’s Bench seeking approximately CAD $840,000 ($592,000), plus interest, for alleged unpaid accrued compensation and benefits up to his resignation from the board on January 1, 2026. The statement of claim has not been served on the Company. As at September 30, 2026, the Company has recorded $319,279 in accounts payable and accrued liabilities for unpaid directors’ fees owed to Mr. Orman for 2021 through 2023 (December 31, 2025 - $319,279). The Company has not yet responded to the claim and is unable to estimate the possible loss, if any, in excess of the amount recorded.
ITEM 1A. RISK FACTORS
As a smaller reporting company, we are not required to provide the information required by this item.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On February 18, 2026, pursuant to an investor relations agreement with another company, the Company agreed to issue 16,000,000 common shares in exchange for services provided.
On June 18, 2026, the Company issued the 30,188,500 common shares pursuant to the settlement agreement. The shares had a fair value of $75,471, based on the closing market price of $0.0025 per share on the settlement date. The shares were issued in full satisfaction of the debt obligation, which had a carrying value of $132,516, including accrued interest, immediately prior to settlement.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
As at September 30, 2026, certain of the Company's notes payable and convertible notes were past their contractual maturity dates and remained unpaid. The Company has not made all required principal and interest payments with respect to certain debt obligations and, accordingly, certain debt instruments are in default. The Company is actively engaged with creditors regarding extensions, settlements, forbearance arrangements and other alternatives to address these obligations. The Company can provide no assurance that additional waivers, extensions, amendments, refinancing arrangements or settlements will be obtained on acceptable terms, or at all.
As at September 30, 2026, the following amounts were past due: convertible notes of $1,007,004 and accrued interest thereon of $434,821; notes payable of $423,738 and accrued interest thereon of $58,503; royalties payable of $513,129; amounts owing under the Formosa lease of $5,041,794, included in accounts payable and comprising unpaid rent and an unpaid lease deposit; and accrued interest on unpaid rent of $1,498,368, for an aggregate amount of $8,977,357.
A further $20,822,401 was not past due but is payable on demand, matures on December 31, 2026, or may be accelerated by the holder as a result of these defaults. This amount comprises the lease liability of $5,771,851 (Note 5); related party loans of $14,382,683, including the Formosa promissory note of $1,995,107, and accrued interest thereon of $652,032; and a demand convertible note of $10,000 and accrued interest thereon of $5,835.
Under the Formosa lease, if a payment default is not cured within five days after notice, the landlord may declare all remaining rent immediately due and payable. As at the date of this Report, Formosa has not issued a notice of default or acceleration under either the lease or the promissory note.
None of these defaults has been cured. As at the date of this Report, total arrears were approximately $9,281,343, including rent, interest, and royalties of approximately $303,986 that became due subsequent to September 30, 2026.
In addition, on March 17, 2025, the Company and its subsidiary, 2323414 Alberta Ltd., entered into a Security and Royalty Agreement with Koze Investments LLC. Under the agreement, an event of default occurs if royalty or lease payments are not made for specified periods. As at September 30, 2026, 2323414 Alberta Ltd. was in default of its payment obligations under the agreement. Koze Investments LLC had agreed to forbear from exercising its rights under the agreement until August 31, 2026. The forbearance period expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities.
The Company's borrowings are discussed further in Notes 2, 4, 5, and 9 to the condensed interim consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
| 44 |
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During
the three and nine months ended September 30, 2026, no director or officer
ITEM 6. EXHIBITS
| 2.1 | Amended and Restated Membership Interest Purchase Agreement, dated November 22, 2023 |
| 3.1 | Bylaws adopted 12/31/10 |
| 3.2 | Certificate of Amendment of Certificate of Incorporation dated 10/22/14 |
| 3.3 | Certificate of Designation of Preferences, Rights and Limitation of Series C Convertible Preferred Stock |
| 4.1 | Letter Agreement between the Company and Koze Investments, LLC and Amir Tal regarding Allocation of Revenue from IMC Cannabis Transaction dated March 17, 2025 |
| 4.2 | Security And Royalty Agreement between the Company and Koze Investments, LLC dated March 17, 2025 |
| 4.3 | Amended and Restated Lease dated January 1, 2025 |
| 4.4 | Amendment No. 1 to Amended and Restated Secured Promissory Note; entered into with Koze Investments LLC and Amir Tal |
| 4.5 | Amendment No. 1 to Amended and Restated Senior Secured Promissory Note; entered into with Koze Investments |
| 4.6 | Secured Promissory Note dated February 26, 2025 |
| 4.7 | Transfer of 2323414 Alberta Ltd. to Elliot Zemel dated March 17, 2025 |
| 4.8 | Forbearance Agreement 2323414 Alberta (CPMD) - Formosa (June 2025) |
| 4.9 | Letter Agreement (Payment Schedule) - A. Tal |
| 4.10 | Payment Schedule (Payment Schedule) - Koze Investments |
| 4.11 | Amendment and Extension to Forbearance Agreement dated effective October 31, 2026 (filed herewith) |
| 4.12 | Amendment to Amended and Restated Secured Promissory Notes dated effective October 31, 2026 (filed herewith) |
| 4.13 | Side Letter Termination and Cancellation Agreement between the Company and Amir Tal dated effective October 31, 2026 (filed herewith) |
| 31.1 | Certification of Chief Executive Officer required by Rule 13a-14(a) under the Exchange Act (filed herewith). |
| 31.2 | Certification of Chief Financial Officer required by Rule 13a-14(a) under the Exchange Act (filed herewith). |
| 32 | Certification of Principal Executive, Financial and Accounting Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (furnished herewith). |
| 101.INS |
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101) |
| 45 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 17, 2026.
| CannaPharmaRx, Inc. | ||
| By: | /s/ Constantine Nkafu | |
| Constantine Nkafu, | ||
| Chief Executive Officer | ||
| By: | /s/ Oliver Foeste | |
| Oliver Foeste, | ||
| Chief Financial Officer | ||
| 46 |